Given Warren Buffet's proclivity for only owning stock of companies that he understands inside and out, these 10 top health care picks with big, dependable dividends make sense now for growth and…
A few big biopharma names were on the move Tuesday morning, and analysts were taking their shot at them.
Markets closed down slightly on Monday and got off to a mixed opening Tuesday. Here's a look at the stocks that were winning and losing in the premarket trading session.
Before markets open on Tuesday, we will hear earnings results from a Dow component, an oil and gas supermajor and the country's largest food distributor.
Here's a look at how markets were shaping up for Monday's opening bell.
Wednesday afternoon's top analyst upgrades and downgrades included Adobe, Altria, Amgen, Beyond Meat, BP, Murphy Oil, Northrop Grumman, Occidental Petroleum, Peloton Interactive, Pfizer, Salesforce.com and 3M.
Tuesday's top analyst upgrades and downgrades included Broadcom, Carrier Global, Canadian Pacific Railway, Coca-Cola, Eli Lilly, Marvell Technology, Pfizer, Regions Financial, Stryker, Synchrony Financial, Tesla and Zillow.
Monday afternoon's top analyst upgrades and downgrades included Activision Blizzard, Lucid, Nokia, Pfizer, SoFi Technologies, Sunrun and Welltower.
Monday’s top analyst upgrades and downgrades included Apple, Coca-Cola, CommScope, Coupa Software, GoPro, HubSpot, Merck, NetApp, Pfizer, Shopify, Spirit Airlines and Warner Music.
Thursday afternoon's top analyst upgrades and downgrades included AbbVie, Allstate, Amgen, Occidental Petroleum, Pfizer, SunPower, Twilio and Yum! Brands.
Broadcom, Pfizer and these other top companies are expected to lift the dividends they pay to shareholders, and their stocks are rated Buy across Wall Street, making them excellent total return candidates.
These five stay-at-home and pharmaceutical stocks perhaps make sense now, on concerns over the Omicron variant of COVID-19. They are Buy rated and pay solid dividends, and they may be solid ideas…
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 400,000 shares of Pfizer on November 11.
One of Cathie Wood's ARK Invest exchange-traded funds sold over 140,000 shares of Pfizer on November 10.
